2004
DOI: 10.1016/s0212-6567(04)79464-0
|View full text |Cite
|
Sign up to set email alerts
|

Control lipídico en prevención secundaria: estudio multicéntrico, observacional en atención primaria

Abstract: Although a clear improved was observed in the control of lipids and other risk factors, there is still a considerable potential to raise standards in secondary prevention of coronary patients followed in primary care concerning control of cardiovascular risk factors, particularly total cholesterol and lipid fractions.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2005
2005
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 16 publications
0
1
0
1
Order By: Relevance
“…Regarding referral rate, lipid pro le alterations are the main CV risk factor in our country and their prevalence rises to 49.3% in some series 22 . Unfortunately, adequate control is achieved in only one-fth of patients 23,24 . This situation, partly explained by an inappropriate use of statins 25,26 justi es the creation and actualitation of territorial LU.…”
Section: Discussionmentioning
confidence: 99%
“…Regarding referral rate, lipid pro le alterations are the main CV risk factor in our country and their prevalence rises to 49.3% in some series 22 . Unfortunately, adequate control is achieved in only one-fth of patients 23,24 . This situation, partly explained by an inappropriate use of statins 25,26 justi es the creation and actualitation of territorial LU.…”
Section: Discussionmentioning
confidence: 99%
“…7 A prevenção secundária das DCV tem como objetivo reduzir o risco de um novo evento cardiovascular e morte, visando melhorar a sobrevida dos pacientes que sofreram o evento cardiovascular, por ser tratar de pacientes de muito alto risco. 8,9 Medidas preventivas, incluindo farmacoterapia, são importantes não apenas para diminuir a morbidade e mortalidade das DCV, mas também porque tem impacto na qualidade de vida. 10,11 Segundo diretrizes internacionais de prevenção secundária das DCV, recomenda-se tratamento medicamentoso ao longo da vida com antiagregantes plaquetários, betabloqueadores, estatinas e inibidores da enzima conversora de angiotensina (IECA).…”
Section: Introductionunclassified